Scotland-based company to showcase synthetic DGLA at InformEx
Pharma-grade DGLA used to treat eczema, psoriasis, arthritis
SAN FRANCISCO, Jan. 27 /PRNewswire/ -- The omega-6 fatty acid DGLA, which has potent anti-inflammatory actions and has not previously been readily accessible from any natural source, is now available in commercial quantities and to a super-pure specification, specialist lipid manufacturer Equateq announced in advance of InformEx 2009.
Equateq announced that it has successfully synthesized omega-6 DGLA (Dihomma-Gamma-Linolenic Acid) up to 98% purity. The company now markets the fatty acid as EQT-101, available to researchers, pharmaceutical and cosmetic companies from gram to kilogram batch sizes. Synthetic DGLA, the first public outcome of Equateq's lipid synthesis programme, which the company has been pursuing at its purpose-built facility in the Western Isles of Scotland, will be presented at InformEx 2009 in San Francisco.
As a precursor to important eicosanoids, hormone-like substances that regulate cell function and have important anti-inflammatory functions, DGLA (20:3 n-6) performs as a 'sister' fatty acid to omega-3 EPA. Thus DGLA has potential to treat conditions such as eczema, psoriasis, asthma and arthritis. Found only in some organ meats and glands, and human breast milk, DGLA has been difficult to source in nature. Previously, researchers relied on sourcing GLA from evening primrose or borage oils, which can convert into DGLA in the body. Now, with the introduction of a synthesized brand, researchers can experiment with direct inputs of DGLA.
"There is a lot of wizardry involved in this, as my team has essentially mimicked processes from within the human body in order to deliver DGLA in a super-pure form," said Equateq CEO Adam Kelliher. "It is a magnificent first result, and we expect to be announcing characterization of several other l
Copyright©2009 PR Newswire.
All rights reserved